Biotech | May 16, 2022
Inmagene receives USFDA IND clearance for a third-generation BTK inhibitor
It is developing the drug candidate to potentially treat immunological diseases
It is developing the drug candidate to potentially treat immunological diseases
Pharmapack offers the platform that enables Bharat Rubber Works to convey its story while simultaneously demonstrating the extraordinary advancements by the company in the field of pharmaceutical packaging
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
The new hospital is expected to open by March'24
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Subscribe To Our Newsletter & Stay Updated
